immuno oncology frontiers world miami


Frank Tufaro

Dr Frank Tufaro

CEO, DNAtrix Therapeutics

Frank Tufaro has extensive experience with the founding, financing, and operation of biotechnology firms. Prior to DNAtrix, Frank was part of the founding team of NeuroVir, a Vancouver-based biotech company with a mission to develop herpes-simplex virus oncolytic vectors for treating cancer. Frank was instrumental in raising venture financing that established NeuroVir as the major player in the field of viral oncology and led to its acquisition by MediGene. Frank also co-founded Nurel Therapeutics, a gene therapy company acquired by Diamyd Medical AB, and Allera Health Products. Previously, Frank was a Professor of Microbiology at the University of British Columbia, wherein his laboratory worked on herpes simplex virus and gene therapy for cancer. Frank received his BSc in Cell and Molecular Biology, a PhD in Developmental Biology from McGill University and was a postdoctoral fellow with Dr. Steve McKnight, at the Fred Hutchinson Cancer Center and the Carnegie Institution of Science. 

  • "Great venue to solidify and harmonize on the current challenges facing this sector - in real time. The caliber of the speakers and session contents was premier. “
    Dolores Baksh
    Innovation Leader, GE Healthcare
  • “A great event to learn about the hurdles that are needed to be overcome to get through the clinic.”
    Devin Bridgen
    Scientist, strategic partnerships, SQZ Biotech
  • "It was a great opportunity to share current data and thinking about the development of therapeutics directed at modulating the immune response to cancer."
    Lance Leopold
    Vice President, Head of Oncology Development, Incyte Corporation
  • "Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field."
    Dr James Trager
    Vice President, Research & Product Development, Dendreon
  • “In the rapidly moving Advanced Therapy market, Phacilitate remains one of the premier events.”
    David James
    CEO, Scinogy